Browse Studies — Arctuva

Phase 2

Evaluation of the Efficacy of Hypomethylating Agent Versus Standard Intensive Chemotherapy Induction Based on 5hmC - a Novel, Blood Epigenetic Marker for Assessing Measurable Residual Disease in Patients With Acute Myeloid Leukemia

This is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC)…

Acute Myeloid Leukemia (AML)Acute Myeloid Leukaemia (AML)

Estimated

~$10 – $6,250

The Methodist Hospital Research InstituteNCT07060001

Phase 1

A Phase 1b/2 Open-Label Study of APVO436 in Combination With Venetoclax and Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with n…

Acute Myeloid Leukemia (AML)

Estimated

~$10 – $8,750

Aptevo TherapeuticsNCT06634394

Phase 2

A Prospective, Multicenter, Randomized, Open-Label, Phase II Study of Salvage BCL2i Plus CLAG-M in Relapsed or Refractory Acute Myeloid Leukemia

This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid …

Relapsed or Refractory Acute Myeloid Leukemia (AML)

Estimated

~$10 – $6,250

H. Lee Moffitt Cancer Center and Research InstituteNCT06660368

Phase 2

A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Venetoclax Plus Decitabine in Patients With AML Who Are Ineligible for Intensive Induction Therapy

The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete R…

Acute Myeloid Leukemia (AML)

Estimated

~$10 – $8,750

Bio-Path Holdings, Inc.NCT02781883